nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—Chlorphenesin—PTGS2—colon cancer	0.00433	0.275	CrCbGaD
Betaxolol—Atenolol—ABCB1—colon cancer	0.00368	0.234	CrCbGaD
Betaxolol—Acebutolol—ABCB1—colon cancer	0.0034	0.216	CrCbGaD
Betaxolol—Metoprolol—ABCB1—colon cancer	0.00287	0.182	CrCbGaD
Betaxolol—Upper respiratory tract infection—Capecitabine—colon cancer	0.00178	0.00181	CcSEcCtD
Betaxolol—Anaemia—Fluorouracil—colon cancer	0.00177	0.0018	CcSEcCtD
Betaxolol—Loss of consciousness—Irinotecan—colon cancer	0.00176	0.00178	CcSEcCtD
Betaxolol—Myalgia—Vincristine—colon cancer	0.00175	0.00177	CcSEcCtD
Betaxolol—Weight increased—Capecitabine—colon cancer	0.00175	0.00177	CcSEcCtD
Betaxolol—Cough—Irinotecan—colon cancer	0.00174	0.00177	CcSEcCtD
Betaxolol—Weight decreased—Capecitabine—colon cancer	0.00174	0.00176	CcSEcCtD
Betaxolol—Hyperglycaemia—Capecitabine—colon cancer	0.00173	0.00176	CcSEcCtD
Betaxolol—Pneumonia—Capecitabine—colon cancer	0.00172	0.00175	CcSEcCtD
Betaxolol—Infestation NOS—Capecitabine—colon cancer	0.00171	0.00174	CcSEcCtD
Betaxolol—Infestation—Capecitabine—colon cancer	0.00171	0.00174	CcSEcCtD
Betaxolol—Depression—Capecitabine—colon cancer	0.00171	0.00173	CcSEcCtD
Betaxolol—Acute coronary syndrome—Capecitabine—colon cancer	0.00169	0.00171	CcSEcCtD
Betaxolol—Lethargy—Methotrexate—colon cancer	0.00169	0.00171	CcSEcCtD
Betaxolol—Discomfort—Irinotecan—colon cancer	0.00168	0.00171	CcSEcCtD
Betaxolol—Neuropathy peripheral—Capecitabine—colon cancer	0.00168	0.0017	CcSEcCtD
Betaxolol—Myocardial infarction—Capecitabine—colon cancer	0.00168	0.0017	CcSEcCtD
Betaxolol—Oedema—Vincristine—colon cancer	0.00167	0.0017	CcSEcCtD
Betaxolol—Stomatitis—Capecitabine—colon cancer	0.00167	0.00169	CcSEcCtD
Betaxolol—Infection—Vincristine—colon cancer	0.00166	0.00169	CcSEcCtD
Betaxolol—Conjunctivitis—Capecitabine—colon cancer	0.00166	0.00169	CcSEcCtD
Betaxolol—Osteoarthritis—Methotrexate—colon cancer	0.00165	0.00168	CcSEcCtD
Betaxolol—Confusional state—Irinotecan—colon cancer	0.00164	0.00167	CcSEcCtD
Betaxolol—Nervous system disorder—Vincristine—colon cancer	0.00164	0.00167	CcSEcCtD
Betaxolol—Thrombocytopenia—Vincristine—colon cancer	0.00164	0.00167	CcSEcCtD
Betaxolol—Oedema—Irinotecan—colon cancer	0.00163	0.00166	CcSEcCtD
Betaxolol—Chest pain—Fluorouracil—colon cancer	0.00163	0.00165	CcSEcCtD
Betaxolol—Myalgia—Fluorouracil—colon cancer	0.00163	0.00165	CcSEcCtD
Betaxolol—Infection—Irinotecan—colon cancer	0.00162	0.00165	CcSEcCtD
Betaxolol—Hyperhidrosis—Vincristine—colon cancer	0.00162	0.00164	CcSEcCtD
Betaxolol—Epistaxis—Capecitabine—colon cancer	0.00161	0.00164	CcSEcCtD
Betaxolol—Discomfort—Fluorouracil—colon cancer	0.00161	0.00164	CcSEcCtD
Betaxolol—Shock—Irinotecan—colon cancer	0.0016	0.00163	CcSEcCtD
Betaxolol—Nervous system disorder—Irinotecan—colon cancer	0.0016	0.00162	CcSEcCtD
Betaxolol—Agranulocytosis—Capecitabine—colon cancer	0.0016	0.00162	CcSEcCtD
Betaxolol—Thrombocytopenia—Irinotecan—colon cancer	0.0016	0.00162	CcSEcCtD
Betaxolol—Anorexia—Vincristine—colon cancer	0.0016	0.00162	CcSEcCtD
Betaxolol—Hyperhidrosis—Irinotecan—colon cancer	0.00158	0.0016	CcSEcCtD
Betaxolol—Confusional state—Fluorouracil—colon cancer	0.00157	0.0016	CcSEcCtD
Betaxolol—Mood swings—Methotrexate—colon cancer	0.00157	0.00159	CcSEcCtD
Betaxolol—Hypotension—Vincristine—colon cancer	0.00156	0.00159	CcSEcCtD
Betaxolol—Bradycardia—Capecitabine—colon cancer	0.00156	0.00159	CcSEcCtD
Betaxolol—Oedema—Fluorouracil—colon cancer	0.00156	0.00159	CcSEcCtD
Betaxolol—Anorexia—Irinotecan—colon cancer	0.00155	0.00158	CcSEcCtD
Betaxolol—Ataxia—Methotrexate—colon cancer	0.00155	0.00158	CcSEcCtD
Betaxolol—Infection—Fluorouracil—colon cancer	0.00155	0.00158	CcSEcCtD
Betaxolol—Rhinitis—Capecitabine—colon cancer	0.00154	0.00156	CcSEcCtD
Betaxolol—Nervous system disorder—Fluorouracil—colon cancer	0.00153	0.00156	CcSEcCtD
Betaxolol—Thrombocytopenia—Fluorouracil—colon cancer	0.00153	0.00155	CcSEcCtD
Betaxolol—Hypoaesthesia—Capecitabine—colon cancer	0.00153	0.00155	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Vincristine—colon cancer	0.00153	0.00155	CcSEcCtD
Betaxolol—Pharyngitis—Capecitabine—colon cancer	0.00152	0.00155	CcSEcCtD
Betaxolol—Tachycardia—Fluorouracil—colon cancer	0.00152	0.00155	CcSEcCtD
Betaxolol—Hypotension—Irinotecan—colon cancer	0.00152	0.00155	CcSEcCtD
Betaxolol—Insomnia—Vincristine—colon cancer	0.00151	0.00154	CcSEcCtD
Betaxolol—Paraesthesia—Vincristine—colon cancer	0.0015	0.00153	CcSEcCtD
Betaxolol—Breast disorder—Methotrexate—colon cancer	0.00149	0.00152	CcSEcCtD
Betaxolol—Anorexia—Fluorouracil—colon cancer	0.00149	0.00151	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00149	0.00151	CcSEcCtD
Betaxolol—Visual impairment—Capecitabine—colon cancer	0.00148	0.0015	CcSEcCtD
Betaxolol—Insomnia—Irinotecan—colon cancer	0.00147	0.0015	CcSEcCtD
Betaxolol—Paraesthesia—Irinotecan—colon cancer	0.00146	0.00149	CcSEcCtD
Betaxolol—Hypotension—Fluorouracil—colon cancer	0.00146	0.00148	CcSEcCtD
Betaxolol—Decreased appetite—Vincristine—colon cancer	0.00146	0.00148	CcSEcCtD
Betaxolol—Dyspnoea—Irinotecan—colon cancer	0.00145	0.00148	CcSEcCtD
Betaxolol—Propranolol—ABCB1—colon cancer	0.00145	0.0921	CrCbGaD
Betaxolol—Gastrointestinal disorder—Vincristine—colon cancer	0.00145	0.00147	CcSEcCtD
Betaxolol—Fatigue—Vincristine—colon cancer	0.00144	0.00147	CcSEcCtD
Betaxolol—Eye disorder—Capecitabine—colon cancer	0.00144	0.00146	CcSEcCtD
Betaxolol—Dyspepsia—Irinotecan—colon cancer	0.00144	0.00146	CcSEcCtD
Betaxolol—Tinnitus—Capecitabine—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Pain—Vincristine—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Constipation—Vincristine—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Asthma—Methotrexate—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Flushing—Capecitabine—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Cardiac disorder—Capecitabine—colon cancer	0.00143	0.00145	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00142	0.00145	CcSEcCtD
Betaxolol—Decreased appetite—Irinotecan—colon cancer	0.00142	0.00144	CcSEcCtD
Betaxolol—Insomnia—Fluorouracil—colon cancer	0.00141	0.00143	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Irinotecan—colon cancer	0.00141	0.00143	CcSEcCtD
Betaxolol—Fatigue—Irinotecan—colon cancer	0.00141	0.00143	CcSEcCtD
Betaxolol—Paraesthesia—Fluorouracil—colon cancer	0.0014	0.00142	CcSEcCtD
Betaxolol—Constipation—Irinotecan—colon cancer	0.00139	0.00142	CcSEcCtD
Betaxolol—Pain—Irinotecan—colon cancer	0.00139	0.00142	CcSEcCtD
Betaxolol—Angiopathy—Capecitabine—colon cancer	0.00139	0.00142	CcSEcCtD
Betaxolol—Dyspnoea—Fluorouracil—colon cancer	0.00139	0.00141	CcSEcCtD
Betaxolol—Immune system disorder—Capecitabine—colon cancer	0.00139	0.00141	CcSEcCtD
Betaxolol—Mediastinal disorder—Capecitabine—colon cancer	0.00138	0.00141	CcSEcCtD
Betaxolol—Chills—Capecitabine—colon cancer	0.00138	0.0014	CcSEcCtD
Betaxolol—Dyspepsia—Fluorouracil—colon cancer	0.00137	0.0014	CcSEcCtD
Betaxolol—Arrhythmia—Capecitabine—colon cancer	0.00137	0.00139	CcSEcCtD
Betaxolol—Decreased appetite—Fluorouracil—colon cancer	0.00136	0.00138	CcSEcCtD
Betaxolol—Alopecia—Capecitabine—colon cancer	0.00136	0.00138	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00135	0.00137	CcSEcCtD
Betaxolol—Mental disorder—Capecitabine—colon cancer	0.00135	0.00137	CcSEcCtD
Betaxolol—Feeling abnormal—Irinotecan—colon cancer	0.00134	0.00137	CcSEcCtD
Betaxolol—Erythema—Capecitabine—colon cancer	0.00134	0.00136	CcSEcCtD
Betaxolol—Malnutrition—Capecitabine—colon cancer	0.00134	0.00136	CcSEcCtD
Betaxolol—Dysuria—Methotrexate—colon cancer	0.00134	0.00136	CcSEcCtD
Betaxolol—Pain—Fluorouracil—colon cancer	0.00134	0.00136	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Methotrexate—colon cancer	0.00133	0.00135	CcSEcCtD
Betaxolol—Body temperature increased—Vincristine—colon cancer	0.00132	0.00134	CcSEcCtD
Betaxolol—Erectile dysfunction—Methotrexate—colon cancer	0.00132	0.00134	CcSEcCtD
Betaxolol—Dysgeusia—Capecitabine—colon cancer	0.00131	0.00133	CcSEcCtD
Betaxolol—Body temperature increased—Irinotecan—colon cancer	0.00129	0.00131	CcSEcCtD
Betaxolol—Feeling abnormal—Fluorouracil—colon cancer	0.00129	0.00131	CcSEcCtD
Betaxolol—Muscle spasms—Capecitabine—colon cancer	0.00129	0.00131	CcSEcCtD
Betaxolol—Pneumonia—Methotrexate—colon cancer	0.00128	0.0013	CcSEcCtD
Betaxolol—Infestation—Methotrexate—colon cancer	0.00127	0.00129	CcSEcCtD
Betaxolol—Infestation NOS—Methotrexate—colon cancer	0.00127	0.00129	CcSEcCtD
Betaxolol—Depression—Methotrexate—colon cancer	0.00127	0.00129	CcSEcCtD
Betaxolol—Vision blurred—Capecitabine—colon cancer	0.00126	0.00128	CcSEcCtD
Betaxolol—Tremor—Capecitabine—colon cancer	0.00125	0.00127	CcSEcCtD
Betaxolol—Stomatitis—Methotrexate—colon cancer	0.00124	0.00126	CcSEcCtD
Betaxolol—Ill-defined disorder—Capecitabine—colon cancer	0.00124	0.00126	CcSEcCtD
Betaxolol—Urticaria—Fluorouracil—colon cancer	0.00124	0.00126	CcSEcCtD
Betaxolol—Conjunctivitis—Methotrexate—colon cancer	0.00124	0.00126	CcSEcCtD
Betaxolol—Anaemia—Capecitabine—colon cancer	0.00124	0.00126	CcSEcCtD
Betaxolol—Body temperature increased—Fluorouracil—colon cancer	0.00123	0.00125	CcSEcCtD
Betaxolol—Hypersensitivity—Vincristine—colon cancer	0.00123	0.00125	CcSEcCtD
Betaxolol—Sweating—Methotrexate—colon cancer	0.00122	0.00124	CcSEcCtD
Betaxolol—Malaise—Capecitabine—colon cancer	0.00121	0.00123	CcSEcCtD
Betaxolol—Epistaxis—Methotrexate—colon cancer	0.0012	0.00122	CcSEcCtD
Betaxolol—Vertigo—Capecitabine—colon cancer	0.0012	0.00122	CcSEcCtD
Betaxolol—Hypersensitivity—Irinotecan—colon cancer	0.0012	0.00122	CcSEcCtD
Betaxolol—Asthenia—Vincristine—colon cancer	0.0012	0.00122	CcSEcCtD
Betaxolol—Syncope—Capecitabine—colon cancer	0.0012	0.00122	CcSEcCtD
Betaxolol—Agranulocytosis—Methotrexate—colon cancer	0.00119	0.00121	CcSEcCtD
Betaxolol—Palpitations—Capecitabine—colon cancer	0.00118	0.0012	CcSEcCtD
Betaxolol—Loss of consciousness—Capecitabine—colon cancer	0.00118	0.00119	CcSEcCtD
Betaxolol—Asthenia—Irinotecan—colon cancer	0.00117	0.00119	CcSEcCtD
Betaxolol—Cough—Capecitabine—colon cancer	0.00117	0.00119	CcSEcCtD
Betaxolol—Hypersensitivity—Fluorouracil—colon cancer	0.00115	0.00117	CcSEcCtD
Betaxolol—Diarrhoea—Vincristine—colon cancer	0.00115	0.00116	CcSEcCtD
Betaxolol—Chest pain—Capecitabine—colon cancer	0.00114	0.00116	CcSEcCtD
Betaxolol—Arthralgia—Capecitabine—colon cancer	0.00114	0.00116	CcSEcCtD
Betaxolol—Myalgia—Capecitabine—colon cancer	0.00114	0.00116	CcSEcCtD
Betaxolol—Pharyngitis—Methotrexate—colon cancer	0.00113	0.00115	CcSEcCtD
Betaxolol—Anxiety—Capecitabine—colon cancer	0.00113	0.00115	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00113	0.00115	CcSEcCtD
Betaxolol—Discomfort—Capecitabine—colon cancer	0.00112	0.00114	CcSEcCtD
Betaxolol—Diarrhoea—Irinotecan—colon cancer	0.00112	0.00113	CcSEcCtD
Betaxolol—Dry mouth—Capecitabine—colon cancer	0.00111	0.00113	CcSEcCtD
Betaxolol—Dizziness—Vincristine—colon cancer	0.00111	0.00112	CcSEcCtD
Betaxolol—Pruritus—Fluorouracil—colon cancer	0.0011	0.00112	CcSEcCtD
Betaxolol—Visual impairment—Methotrexate—colon cancer	0.0011	0.00112	CcSEcCtD
Betaxolol—Confusional state—Capecitabine—colon cancer	0.0011	0.00112	CcSEcCtD
Betaxolol—Oedema—Capecitabine—colon cancer	0.00109	0.00111	CcSEcCtD
Betaxolol—Infection—Capecitabine—colon cancer	0.00108	0.0011	CcSEcCtD
Betaxolol—Dizziness—Irinotecan—colon cancer	0.00108	0.0011	CcSEcCtD
Betaxolol—Shock—Capecitabine—colon cancer	0.00107	0.00109	CcSEcCtD
Betaxolol—Nervous system disorder—Capecitabine—colon cancer	0.00107	0.00109	CcSEcCtD
Betaxolol—Eye disorder—Methotrexate—colon cancer	0.00107	0.00109	CcSEcCtD
Betaxolol—Diarrhoea—Fluorouracil—colon cancer	0.00107	0.00109	CcSEcCtD
Betaxolol—Thrombocytopenia—Capecitabine—colon cancer	0.00107	0.00109	CcSEcCtD
Betaxolol—Tinnitus—Methotrexate—colon cancer	0.00107	0.00108	CcSEcCtD
Betaxolol—Tachycardia—Capecitabine—colon cancer	0.00107	0.00108	CcSEcCtD
Betaxolol—Vomiting—Vincristine—colon cancer	0.00106	0.00108	CcSEcCtD
Betaxolol—Cardiac disorder—Methotrexate—colon cancer	0.00106	0.00108	CcSEcCtD
Betaxolol—Skin disorder—Capecitabine—colon cancer	0.00106	0.00108	CcSEcCtD
Betaxolol—Rash—Vincristine—colon cancer	0.00106	0.00107	CcSEcCtD
Betaxolol—Hyperhidrosis—Capecitabine—colon cancer	0.00105	0.00107	CcSEcCtD
Betaxolol—Dermatitis—Vincristine—colon cancer	0.00105	0.00107	CcSEcCtD
Betaxolol—Headache—Vincristine—colon cancer	0.00105	0.00107	CcSEcCtD
Betaxolol—Anorexia—Capecitabine—colon cancer	0.00104	0.00106	CcSEcCtD
Betaxolol—Angiopathy—Methotrexate—colon cancer	0.00104	0.00105	CcSEcCtD
Betaxolol—Vomiting—Irinotecan—colon cancer	0.00104	0.00105	CcSEcCtD
Betaxolol—Immune system disorder—Methotrexate—colon cancer	0.00103	0.00105	CcSEcCtD
Betaxolol—Dizziness—Fluorouracil—colon cancer	0.00103	0.00105	CcSEcCtD
Betaxolol—Mediastinal disorder—Methotrexate—colon cancer	0.00103	0.00105	CcSEcCtD
Betaxolol—Rash—Irinotecan—colon cancer	0.00103	0.00104	CcSEcCtD
Betaxolol—Dermatitis—Irinotecan—colon cancer	0.00103	0.00104	CcSEcCtD
Betaxolol—Chills—Methotrexate—colon cancer	0.00103	0.00104	CcSEcCtD
Betaxolol—Headache—Irinotecan—colon cancer	0.00102	0.00104	CcSEcCtD
Betaxolol—Hypotension—Capecitabine—colon cancer	0.00102	0.00104	CcSEcCtD
Betaxolol—Alopecia—Methotrexate—colon cancer	0.00101	0.00103	CcSEcCtD
Betaxolol—Mental disorder—Methotrexate—colon cancer	0.001	0.00102	CcSEcCtD
Betaxolol—Erythema—Methotrexate—colon cancer	0.000995	0.00101	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—colon cancer	0.000995	0.00101	CcSEcCtD
Betaxolol—Nausea—Vincristine—colon cancer	0.000994	0.00101	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000994	0.00101	CcSEcCtD
Betaxolol—Vomiting—Fluorouracil—colon cancer	0.000993	0.00101	CcSEcCtD
Betaxolol—Insomnia—Capecitabine—colon cancer	0.000987	0.001	CcSEcCtD
Betaxolol—Rash—Fluorouracil—colon cancer	0.000985	0.001	CcSEcCtD
Betaxolol—Dermatitis—Fluorouracil—colon cancer	0.000984	0.000999	CcSEcCtD
Betaxolol—Paraesthesia—Capecitabine—colon cancer	0.00098	0.000996	CcSEcCtD
Betaxolol—Headache—Fluorouracil—colon cancer	0.000978	0.000994	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—colon cancer	0.000975	0.00099	CcSEcCtD
Betaxolol—Dyspnoea—Capecitabine—colon cancer	0.000973	0.000988	CcSEcCtD
Betaxolol—Nausea—Irinotecan—colon cancer	0.000968	0.000984	CcSEcCtD
Betaxolol—Dyspepsia—Capecitabine—colon cancer	0.000961	0.000976	CcSEcCtD
Betaxolol—Decreased appetite—Capecitabine—colon cancer	0.000949	0.000964	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Capecitabine—colon cancer	0.000942	0.000957	CcSEcCtD
Betaxolol—Fatigue—Capecitabine—colon cancer	0.000941	0.000956	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—colon cancer	0.000938	0.000953	CcSEcCtD
Betaxolol—Constipation—Capecitabine—colon cancer	0.000933	0.000948	CcSEcCtD
Betaxolol—Pain—Capecitabine—colon cancer	0.000933	0.000948	CcSEcCtD
Betaxolol—Nausea—Fluorouracil—colon cancer	0.000928	0.000942	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—colon cancer	0.000924	0.000938	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—colon cancer	0.00092	0.000935	CcSEcCtD
Betaxolol—Feeling abnormal—Capecitabine—colon cancer	0.000899	0.000914	CcSEcCtD
Betaxolol—Malaise—Methotrexate—colon cancer	0.000898	0.000912	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—colon cancer	0.000894	0.000909	CcSEcCtD
Betaxolol—Cough—Methotrexate—colon cancer	0.000869	0.000882	CcSEcCtD
Betaxolol—Urticaria—Capecitabine—colon cancer	0.000867	0.000881	CcSEcCtD
Betaxolol—Body temperature increased—Capecitabine—colon cancer	0.000863	0.000876	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—colon cancer	0.000847	0.000861	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—colon cancer	0.000847	0.000861	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—colon cancer	0.000847	0.000861	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000842	0.000855	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—colon cancer	0.000837	0.000851	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—colon cancer	0.000819	0.000832	CcSEcCtD
Betaxolol—Infection—Methotrexate—colon cancer	0.000807	0.00082	CcSEcCtD
Betaxolol—Hypersensitivity—Capecitabine—colon cancer	0.000804	0.000817	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—colon cancer	0.000797	0.000809	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—colon cancer	0.000795	0.000808	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—colon cancer	0.000789	0.000802	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—colon cancer	0.000785	0.000798	CcSEcCtD
Betaxolol—Asthenia—Capecitabine—colon cancer	0.000783	0.000795	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—colon cancer	0.000774	0.000787	CcSEcCtD
Betaxolol—Pruritus—Capecitabine—colon cancer	0.000772	0.000784	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—colon cancer	0.000759	0.000771	CcSEcCtD
Betaxolol—Diarrhoea—Capecitabine—colon cancer	0.000747	0.000759	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00074	0.000752	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—colon cancer	0.000735	0.000746	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—colon cancer	0.000729	0.000741	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—colon cancer	0.000724	0.000736	CcSEcCtD
Betaxolol—Dizziness—Capecitabine—colon cancer	0.000722	0.000733	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—colon cancer	0.000715	0.000726	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—colon cancer	0.000706	0.000717	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—colon cancer	0.000701	0.000713	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—colon cancer	0.0007	0.000712	CcSEcCtD
Betaxolol—Pain—Methotrexate—colon cancer	0.000695	0.000706	CcSEcCtD
Betaxolol—Vomiting—Capecitabine—colon cancer	0.000694	0.000705	CcSEcCtD
Betaxolol—Rash—Capecitabine—colon cancer	0.000688	0.000699	CcSEcCtD
Betaxolol—Dermatitis—Capecitabine—colon cancer	0.000687	0.000698	CcSEcCtD
Betaxolol—Headache—Capecitabine—colon cancer	0.000684	0.000695	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—colon cancer	0.000669	0.00068	CcSEcCtD
Betaxolol—Nausea—Capecitabine—colon cancer	0.000648	0.000659	CcSEcCtD
Betaxolol—Urticaria—Methotrexate—colon cancer	0.000645	0.000656	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—colon cancer	0.000642	0.000652	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—colon cancer	0.000599	0.000608	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—colon cancer	0.000583	0.000592	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—colon cancer	0.000575	0.000584	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—colon cancer	0.000556	0.000565	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—colon cancer	0.000537	0.000546	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—colon cancer	0.000517	0.000525	CcSEcCtD
Betaxolol—Rash—Methotrexate—colon cancer	0.000512	0.00052	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—colon cancer	0.000512	0.00052	CcSEcCtD
Betaxolol—Headache—Methotrexate—colon cancer	0.000509	0.000517	CcSEcCtD
Betaxolol—Nausea—Methotrexate—colon cancer	0.000483	0.00049	CcSEcCtD
